DeLee Maxson

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

Robert C. Doebele, Xian Lu, Christopher Sumey et al. · Cancer · 2012 · 279 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (<i>ALK</i>) gene rearrangement, <i>ALK</i> signal copy number, and response to crizotinib therapy in <i>ALK</i> fluorescence in situ hybridization–positive nonsmall cell lung cancer

D. Ross Camidge, Mariana F. Theodoro, DeLee Maxson et al. · Cancer · 2012 · 93 citations · Full text

Medicine, Genetics, Oncology +16

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

Andrew Weickhardt, Robert C. Doebele, Ana B. Oton et al. · Journal of Thoracic Oncology · 2012 · 50 citations

Medicine, Oncology, Pharmacotherapy +13

Native and rearranged ALK copy number and rearranged cell count in non–small cell lung cancer

D. Ross Camidge, Margaret C. Skokan, Porntip Kiatsimkul et al. · Cancer · 2013 · 46 citations · Full text

Medicine, Molecular Genetics, Oncology +16

Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

Eamon M. Berge, Xian Lu, DeLee Maxson et al. · Clinical Lung Cancer · 2013 · 25 citations

Medicine, Oncology, Pharmacology +13